The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system

Genome Medicine

Volumn 5, Issue 10, 2013, Pages

  Gharani, Neda ^a   Keller, Margaret A ^a,b   Stack, Catharine B ^a,c   Hodges, Laura M ^a   Schmidlen, Tara J ^a   Lynch, Daniel E ^a   Gordon, Erynn S ^a   Christman, Michael F ^a  

^a NIGMS Human Mutant Cell Repository   (United States)

^b AMERICAN RED CROSS   (United States)

^c Annals of Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CLOPIDOGREL; CODEINE; DIAZEPAM; FLUOROURACIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MERCAPTOPURINE; METOPROLOL; PRESCRIPTION DRUG; PROTON PUMP INHIBITOR; SIMVASTATIN; TAMOXIFEN; WARFARIN;

ARTICLE; CORIELL PERSONALIZED MEDICINE COLLABORATIVE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESPONSE; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHARMACOGENOMICS APPRAISAL EVIDENCE SCORING AND INTERPRETATION SYSTEM; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 84885525308     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm499     Document Type: Article

References (44)

1. Vizirianakis IS. Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping. Clin Pharmacokinet 2007, 46:807-824. 10.2165/00003088-200746100-00001, 17854232.
2. Chung WK. Implementation of genetics to personalize medicine. Gend Med 2007, 4:248-265. 10.1016/S1550-8579(07)80044-1, 18022591.
3. McCarthy AD, Kennedy JL, Middleton LT. Pharmacogenetics in drug development. Philos Trans R Soc Lond B Biol Sci 2005, 360:1579-1588. 10.1098/rstb.2005.1688, 1569527, 16096107.
4. Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 2008, 7:807-817. 10.1038/nrd2593, 18806753.
5. Winston A, Hatzimichael E, Marvin V, Stebbing J, Bower M. Host pharmacogenetics in the treatment of HIV and cancer. Curr Drug Saf 2006, 1:107-116. 10.2174/157488606775252683, 18690920.
6. Tonon G, Anderson KC. Moving toward individualized cancer therapies. Clin Cancer Res 2008, 14:4682-4684. 10.1158/1078-0432.CCR-08-1134, 18676734.
7. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov 2004, 3:763-769. 10.1038/nrd1499, 15340386.
8. Burczynski ME, Oestreicher JL, Cahilly MJ, Mounts DP, Whitley MZ, Speicher LA, Trepicchio WL. Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. Curr Mol Med 2005, 5:83-102. 10.2174/1566524053152933, 15720272.
9. Relling MV, Hoffman JM. Should pharmacogenomic studies be required for new drug approval?. Clin Pharmacol Ther 2007, 81:425-428. 10.1038/sj.clpt.6100097, 17339872.
10. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010, 363:301-304. 10.1056/NEJMp1006304, 20551152.
11. Lesko LJ, Zineh I. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. Pharmacogenomics 2010, 11:507-512. 10.2217/pgs.10.16, 20350131.
12. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, Delaney JT, Bowton E, Brothers K, Johnson K, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012, 92:87-95. 10.1038/clpt.2011.371, 3581305, 22588608.
13. Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012, 379:1705-1711. 10.1016/S0140-6736(12)60161-5, 22464343.
14. Gatsonis C. The promise and realities of comparative effectiveness research. Stat Med 2010, 29:1977-1981. discussion 1996-1977, 10.1002/sim.3936, 3544942, 20683886.
15. Epstein RS, Moyer TP, Aubert RE, Kane DJ O, Xia F, Verbrugge RR, Gage BF, Teagarden JR. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010, 55:2804-2812. 10.1016/j.jacc.2010.03.009, 20381283.
16. Keller M, Gordon ES, Stack CB, Gharani N, Schmidlen TJ, Mintzer J, Pallies J, Gerry N, Christman MF. The coriell personalized medicine collaborative: a prospective study of the utility of personalized medicine" Pers Med 2010, 7:301-317.
17. Stack CB, Gharani N, Gordon ES, Schmidlen T, Christman MF, Keller MA. Genetic risk estimation in the coriell personalized medicine collaborative. Genet Med 2011, 13:131-139. 10.1097/GIM.0b013e318201164c, 21233721.
18. FDA Table of Pharmacogenomic Biomarkers in Drug labels. [http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm].
19. PharmGKB. [https://www.pharmgkb.org/].
20. CYP450 Drug Interaction Table. [http://medicine.iupui.edu/clinpharm/ddis/table.aspx].
21. Pharmacy Times Top 200 Drugs. [http://www.pharmacytimes.com/publications/issue/2012/July2012/Top-200-Drugs-of-2011].
22. Drug Topics. [http://drugtopics.modernmedicine.com/].
23. Robarge JD, Li L, Desta Z, Nguyen A, Flockhart DA. The star-allele nomenclature: retooling for translational genomics. Clin Pharmacol Ther 2007, 82:244-248. 10.1038/sj.clpt.6100284, 17700589.
24. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 2001, 1:167-170. 10.1038/sj.tpj.6500035, 11908751.
25. Sim SC, Ingelman-Sundberg M. The human cytochrome P450 (CYP) allele nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 2010, 4:278-281. 10.1186/1479-7364-4-4-278, 3525213, 20511141.
26. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 2002, 30:1311-1319. 10.1124/dmd.30.12.1311, 12433797.
27. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006, 58:521-590. 10.1124/pr.58.3.6, 16968950.
28. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:23-37. 10.1007/s00210-003-0832-2, 14618296.
29. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008, 83:234-242. 10.1038/sj.clpt.6100406, 17971818.
30. Schenk PW, Van Fessem MA, Verploegh-Van Rij S, Mathot RA, Van Gelder T, Vulto AG, Van Vliet M, Lindemans J, Bruijn JA, Van Schaik RH. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 2008, 13:597-605. 10.1038/sj.mp.4002057, 17667959.
31. Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004, 50:1623-1633. 10.1373/clinchem.2003.030825, 15205367.
32. Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lotsch J, Roots I, Brockmoller J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007, 7:257-265. 10.1038/sj.tpj.6500406, 16819548.
33. CPMC Advisory Boards. [http://cpmc1.coriell.org/about-the-cpmc-study/advisory-boards].
34. CPMC Demo Accounts. [http://cpmc.coriell.org/Demo/DemoPeople.aspx].
35. Goetz MBD, Klein T, International Tamoxifen Pharmacogenomics Consortium Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: findings from the international tamoxifen pharmacogenomics consortium. Cancer Res 2009, 69:Abstract nr 33. International Tamoxifen Pharmacogenomics Consortium.
36. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed M, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011, 90:625-629. 10.1038/clpt.2011.185, 3187550,3187550, 21900891.
37. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005, 127:2049-2056. 10.1378/chest.127.6.2049, 15947319.
38. Strom CM, Goos D, Crossley B, Zhang K, Buller-Burkle A, Jarvis M, Quan F, Peng M, Sun W. Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genet Med 2012, 14:95-100. 10.1038/gim.0b013e3182329870, 22237437.
39. Relling MV, Guchelaar HJ, Roden DM, Klein TE. Pharmacogenetics: call to action. Clin Pharmacol Ther 2011, 90:507. author reply 507-508.
40. Swen JJ, Nijenhuis M, de Boer A, Grandia L, der Zee AH M-V, Mulder H, Rongen GA, Van Schaik RH, Schalekamp T, Touw DJ, et al. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther 2011, 89:662-673. 10.1038/clpt.2011.34, 21412232.
41. Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, de Boer A, Conemans JM, Egberts TC, Klungel OH, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther 2008, 83:781-787. 10.1038/sj.clpt.6100507, 18253145.
42. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO, Group EW. The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP working group. Genet Med 2009, 11:3-14. 10.1097/GIM.0b013e318184137c, 2743609, 18813139.
43. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR. Clinical pharmacogenetics implementation C: clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011, 90:328-332. 10.1038/clpt.2011.132, 3234301,3234301, 21716271.
44. Pare G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010, 363:1704-1714. 10.1056/NEJMoa1008410, 20979470.